Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Avadel Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Greg Divis
İcra Kurulu Başkanı
US$985.2k
Toplam tazminat
| CEO maaş yüzdesi | 60.9% |
| CEO görev süresi | 5.8yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 4.8yrs |
| Yönetim Kurulu ortalama görev süresi | 6.3yrs |
Son yönetim güncellemeleri
Recent updates
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10
Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05
CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$106m |
| Mar 31 2024 | n/a | n/a | -US$157m |
| Dec 31 2023 | US$985k | US$600k | -US$160m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$142m |
| Dec 31 2022 | US$754k | US$561k | -US$137m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$90m |
| Dec 31 2021 | US$3m | US$545k | -US$77m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$56m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$3m | US$520k | US$7m |
| Sep 30 2020 | n/a | n/a | US$16m |
| Jun 30 2020 | n/a | n/a | US$18m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$1m | US$472k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$94m |
| Jun 30 2019 | n/a | n/a | -US$101m |
| Mar 31 2019 | n/a | n/a | -US$96m |
| Dec 31 2018 | US$685k | US$417k | -US$95m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | n/a | n/a | US$30m |
| Dec 31 2017 | US$1m | US$375k | US$68m |
Tazminat ve Piyasa: Greg 'nin toplam tazminatı ($USD 985.20K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.54M ).
Tazminat ve Kazançlar: Greg şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Greg Divis (57 yo)
5.8yrs
Görev süresi
US$985,200
Tazminat
Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$985.20k | Veri yok | |
| Senior VP | 4.8yrs | US$663.14k | 0.084% $ 1.1m | |
| Chief Commercial Officer | 3.7yrs | US$770.95k | 0% $ 0 | |
| General Counsel & Company Secretary | 4.1yrs | Veri yok | 0.0091% $ 115.2k | |
| VP of Corporate and Business Development | 9.3yrs | Veri yok | 0.17% $ 2.1m | |
| Vice President of Sales | 8.2yrs | Veri yok | Veri yok | |
| Vice President of People & Culture | 3.4yrs | Veri yok | Veri yok | |
| Consultant | 5.5yrs | US$982.54k | Veri yok | |
| Senior Vice President of Technical Operations | 4.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Medical & Clinical Affairs | no data | Veri yok | Veri yok |
4.8yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: AVDL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$985.20k | Veri yok | |
| Member of Scientific Advisory Board | 19.8yrs | Veri yok | Veri yok | |
| Independent Director | 4.8yrs | US$449.84k | 0.070% $ 877.3k | |
| Independent Director | less than a year | Veri yok | Veri yok | |
| Independent Director | 7.3yrs | US$459.84k | 0.086% $ 1.1m | |
| Member of Scientific Advisory Board | 19.8yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 5.8yrs | US$452.34k | 0.17% $ 2.2m | |
| Chairman of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Non-Executive Chairman of the Board | 6.3yrs | US$482.34k | 0.13% $ 1.6m | |
| Independent Director | 6.3yrs | US$452.34k | 0.054% $ 685.9k |
6.3yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AVDL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).